COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,740 Articles (22,502 medRxiv, 8,238 bioRxiv)

Most recent first Previous |  Page 2182: Articles 21811-21820  | Next

Vent-Lock: A 3D Printed Ventilator Multiplexer to Enhance the Capacity of Treating Patients with COVID-19
Xun, H., Shallal, C., Unger, J., Tao, R., Torres, A., Vladimirov, M., Frye, J., Singhala, M., Horne, B., Yesantharao, P., Kim, B. S., Burke, B., Montana, M., Talcott, M., Winters, B., Frisella, M., Kushner, B., Sacks, J., Guest, J., Kang, S. H., Caffrey, J.
10.1101/2020.09.16.20195230 — Posted: 2020-09-22
Uncovering clinical risk factors and prediction of severe COVID-19: A machine learning approach based on UK Biobank data
WONG, K. C. Y., So, H.-C.
10.1101/2020.09.18.20197319 — Posted: 2020-09-22 Discussion: Onsite
Diagnosis value of SARS-CoV-2 antigen/antibody combined testing using rapid diagnostic tests at hospital admission
Veyrenche, N., Bollore, K., Pisoni, A., Bedin, A.-S., Mondain, A.-M., Ducos, J., Segondy, M., Montes, B., Pastor, P., Morquin, D., Makinson, A., Le Moing, V., Van De Perre, P., Foulongne, V., Tuaillon, E.
10.1101/2020.09.19.20197855 — Posted: 2020-09-22
Forecasting daily COVID-19 confirmed, deaths and recovered cases using univariate time series models: A case of Pakistan study
Iftikhar, H., Iftikhar, M.
10.1101/2020.09.20.20198150 — Posted: 2020-09-22
Ruling In and Ruling Out COVID-19: Computing SARS-CoV-2 Infection Risk From Symptoms, Imaging and Test Data.
D'Ambrosia, C., Christensen, H., Aronoff-Spencer, E.
10.1101/2020.09.18.20197582 — Posted: 2020-09-22
Investigation of COVID-19 comorbidities reveals genes and pathways coincident with the SARS-CoV-2 viral disease
Dolan, M. E., Hill, D. P., Mukherjee, G., McAndrews, M. S., Chesler, E. J., Blake, J. A.
10.1101/2020.09.21.306720 — Posted: 2020-09-21
Cryo-EM structure of S-Trimer, a subunit vaccine candidate for COVID-19
Ma, J., Su, D., Huang, X., Liang, Y., Ma, Y., Liang, P., Zheng, S.
10.1101/2020.09.21.306357 — Posted: 2020-09-21
Comparative analysis reveals the species-specific genetic determinants of ACE2 required for SARS-CoV-2 entry
Ren, W., Hu, G., Zhao, X., Wang, Y., Shi, H., Lan, J., Zhu, Y., Wu, J., Kenney, D. J., Florian, D., Tong, Y., Zhong, J., Xie, Y., Wang, X., Yuan, Z., Zhou, D., Zhang, R., Ding, Q.
10.1101/2020.09.20.297242 — Posted: 2020-09-21
A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody
Wu, N. C., Yuan, M., Bangaru, S., Huang, D., Zhu, X., Lee, C.-C. D., Turner, H. L., Peng, L., Yang, L., Nemazee, D., Ward, A. B., Wilson, I. A.
10.1101/2020.09.21.305441 — Posted: 2020-09-21 Discussion: Onsite | Offsite
Critical Interactions Between the SARS-CoV-2 Spike Glycoprotein and the Human ACE2 Receptor
Taka, E., Yilmaz, S. Z., Golcuk, M., Kilinc, C., Aktas, U., Yildiz, A., Gur, M.
10.1101/2020.09.21.305490 — Posted: 2020-09-21

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).